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Available online xxxxIn the last decade, induced pluripotent stem (iPS) cells have revolutionized the utility of human in vitromodels of
neurological disease. The iPS-derived and differentiated cells allow researchers to study the impact of a distinct
cell type in health and disease as well as performing therapeutic drug screens on a human genetic background.
In particular, clinical trials for Alzheimer's disease (AD) have been failing. Two of the potential reasons are ﬁrst,
the species gap involved in proceeding from initial discoveries in rodent models to human studies, and second,
an unsatisfying patient stratiﬁcation, meaning subgrouping patients based on the disease severity due to the
lack of phenotypic and genetic markers. iPS cells overcome this obstacles and will improve our understanding
of disease subtypes in AD. They allow researchers conducting in depth characterization of neural cells from
both familial and sporadic AD patients as well as preclinical screens on human cells.
In this review,we brieﬂy outline the status quo of iPS cell research in neurological diseases alongwith the general
advantages and pitfalls of these models. We summarize how genome-editing techniques such as CRISPR/Cas9
will allow researchers to reduce the problem of genomic variability inherent to human studies, followed by re-
cent iPS cell studies relevant to AD. We then focus on current techniques for the differentiation of iPS cells into
neural cell types that are relevant to AD research. Finally, we discuss how the generation of three-dimensional
cell culture systems will be important for understanding AD phenotypes in a complex cellular milieu, and how
both two- and three-dimensional iPS cellmodels can provide platforms for drug discovery and translational stud-
ies into the treatment of AD.
© 2015 Elsevier Inc. All rights reserved.Keywords:
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Alzheimer's disease (AD) is an age-related neurodegenerative
disorder associated with severe memory impairments and has become
the 6th leading cause of death in the United States (www.alz.org).
The ﬁrst case of AD was published in 1907 by Dr. Aloysius “Alois”
Alzheimer, who described a 51-year-old woman with serious memory
loss. Post-mortem analysis of her brain showed severe brain atrophy
andneuronal loss, aswell as the presence of dense extracellular deposits
and intracellular aggregates within neurons (Alzheimer, 1911; Graeber
et al., 1997). These features were eventually identiﬁed as amyloid
plaques and neuroﬁbrillary tangles, respectively (Glenner and Wong,
1984; Grundke-Iqbal et al., 1986; Kosik et al., 1986), and the condition
became known as Alzheimer's disease (Kraepelin, 1910).
Amyloid plaques are extracellular accumulations of β-amyloid (Aβ)
peptides that are derived from the proteolytic processing of the β-
amyloid precursor protein (APP) (Goldgaber et al., 1987; Kang et al.,
1987; Robakis et al., 1987; Tanzi et al., 1987). The γ-secretase
complex cleaves APP at different positions, generating different size
amyloidogenic peptides Aβ43, Aβ42, Aβ40, Aβ38, and Aβ37 (De Strooper,
2010). Of these, Aβ40 is the most abundant in both healthy and AD
brain tissue, whereas the Aβ42 variant has been shown to be likely the
most deleterious (Jarrett et al., 1993; Portelius et al., 2010). Much of
our understanding of the mechanisms underlying AD pathology
comes from a small population of individuals with early-onset familial
AD (fAD). These cases harbor causal mutations involving primarily the
Aβ processing enzymes, presenilin 1 and 2 (PSEN1, PSEN2), which are
part of the γ-secretase complex (Levy-Lahad et al., 1995a; Levy-Lahad
et al., 1995b; Rogaev et al., 1995; Schellenberg et al., 1993), ormutations
within or duplications of the APP gene itself (Goate et al., 1991; Goate,
2006; St George-Hyslop et al., 1987).
The second deﬁning characteristic of AD is the presence of neuroﬁ-
brillary tangles (NFTs) comprised of intracellular accumulations of the
microtubule-associated protein tau in affected neurons (Ballatore
et al., 2007). The extent of tau pathology in human AD has been
shown to correlate well to disease severity (Braak and Braak, 1991).
Mutations in the gene encoding tau (MAPT) have been found to be
causal for fronto-temporal dementia, although MAPT mutations have
not been described in AD (Hutton et al., 1998; Spillantini et al., 1998).
Overexpression of tau protein in mouse models has been shown to
disrupt intracellular trafﬁcking (Zhang et al., 2006), to induce axonal
degeneration (Spittaels et al., 1999), and the humanized tau overex-
pression leads to neuroﬁbrillary tangles formation in vivo (for review,
see (Götz et al., 2007)). A number of promising drugs have reached
late-stage (Phase III) clinical testing, however then failed to prevent
cognitive decline (Doody et al., 2013; Doody et al., 2014; Salloway et al.,
2014). The reasons are likely two-fold: ﬁrst, the lack of human data for
the successful stratiﬁcation (separating patient population) according to
disease phenotypes and/or genetic risk proﬁles (Blennow, 2010;
Wolozin, 2012), and second, the species gap. Risk factors present in
humans may not be adequately modeled in rodents. For example, while
variants in theAPOE gene are the strongest genetic risk factors for sporad-
ic AD identiﬁed to date (Bertram et al., 2008; Corder et al., 1993; Farrer
et al., 1997), the rodent genome has only one version of this gene.
A number of elegant mouse models have allowed the study of AD
phenotypes in vivo in the brain, and have resulted in the basis of our cur-
rent mechanistic understanding of the disease. However, a commonPlease cite this article as: Mungenast, A.E., et al., Modeling Alzheimer's
Neurosci. (2015), http://dx.doi.org/10.1016/j.mcn.2015.11.010drawback to these models is that they typically only capture speciﬁc
aspects of AD phenotypes such as Aβ plaques or NFTs, but rarely the en-
tire disease spectrum (Webster et al., 2014). Moreover, most mouse
models focus only on the causative mutations in familial AD (fAD),
such as those in the genes encoding presenilin 1 and 2 (PSEN1, PSEN2)
and the amyloid-precursor protein (APP). These cases represent an ex-
tremely small percentage of the overall human AD burden; though
models of fAD are invaluable, the majority of AD cases are sporadic
(sAD). The genetic underpinnings of sADmay result from a combinato-
rial or additive effect of single nucleotide polymorphisms (SNPs) identi-
ﬁed in genome-wide association studies (GWAS) (Lambert et al., 2013),
while disease penetrance may depend on a host of non-genetic risk
factors, such as age, head trauma, diabetes, lifetime stress, and environ-
mental toxins, amongst others. Studying the distinct impact of AD-
associated SNPs in mouse models is challenging, as these variants are
often found in non-coding regions of the human genome. Using
even the latest andmost rapid genomeediting techniques to insertmul-
tiple SNPs in homologousmouse genome regionswould be onerous, ex-
pensive, and could be considered a high-risk undertaking. It is often not
knownwhether a single SNP is disease causing, or whether it's a combi-
nation of several SNPs particularly as a number of different SNPs are
commonly ascribed to a single locus.
2. Human induced pluripotent stem (iPS) cells
We will summarize the history, generation, and differentiation of
human iPS cells only brieﬂy, as many excellent reviews have covered
these topics (Bouwman and de Laat, 2015; Parent and Anderson,
2015; Telias and Ben-Yosef, 2014). One fundamental question in the
regenerationﬁeld is to ﬁnd cells thatmaintain the capability to differen-
tiate into the three germ layers: endoderm, mesoderm, and ectoderm.
Embryonic stem (ES) cells have this “pluripotency” capability (Evans
and Kaufman, 1981; Martin, 1981; Thomson et al., 1998). However,
ethical issues tempered the initial excitement for human ES cells and
therefore alternative strategies were needed (Hotta, 2008; Kamm,
2005). An important step was the discovery that the content of an
oocyte's cytoplasm contained factors crucial for reprogramming somat-
ic cells to an embryonic-like stage (Cowan et al., 2005; Tada et al., 2001;
Wilmut et al., 1997). Takahashi et al. screened 24 of these factors and
demonstrated that Oct3/4, Sox2, c-Myc, and Klf4 induced pluripotent
stem cells from adult mouse ﬁbroblasts (Takahashi and Yamanaka,
2006). A year later, the same group showed that they could reprogram
human ﬁbroblasts with these four “Yamanaka factors” into human
pluripotent stem cells (Takahashi et al., 2007). Other groups have
generated similarly pluripotent cells from other peripheral cells, such
as blood cells (Okita et al., 2013) or urine-derived epithelial cells
(Zhou et al., 2012). To distinguish these pluripotent stem cells from ES
cells, the cells were named “induced pluripotent stem” (iPS) cells.
Currently, much debate exists over the bestmethod for reprogramming
somatic cells into iPS cells, as well as how to assess the “stemness” of an
iPS cell as compared to an ES cell line (Bock et al., 2011; Hanna et al.,
2010; Lister et al., 2011). It is important to keep inmind that exogenous
factors, genetic background, and epigenetic of tissue origin of cells inﬂu-
ences naïve pluripotency (Hanna et al., 2010). Therefore certain differ-
ences on the epigenetic landscape are expected to exist between ES
and iPS cells (Bock et al., 2011; Lister et al., 2011). Nevertheless, the
advent of iPS cells allows one to generate any cell type of interestdisease with human induced pluripotent stem (iPS) cells, Mol. Cell.
Fig. 1.Using human patient derived induced pluripotent stem (iPS) cells to model Alzheimer's disease (AD) pathology. This model ﬁgure illustrates the logical path of experiments using
iPS cells to study AD phenotypes and screen for novel therapeutics. Somatic cells (blood, skin, etc.) are reprogrammed in vitro into iPS cell colonies. At this point, or later, genome-editing
techniques can be used to create isogenic lines containing speciﬁc mutations or transgenes. Techniques exist to differentiate the iPS cells into neural cells that include neurons, microglia,
astrocytes and oligodendrocytes, as well as neural progenitor cells (not pictured). From the iPS cell stage, self-organizing tissue cytosystems, or organoids, can also be created in three-
dimensional culture. Neural cells differentiated from iPS lines with sporadic or familial AD (sAD or fAD) backgrounds can display a number of AD-like phenotypes that can be assayed
in vitro. These include amyloid β peptide production and, in the case of three-dimensional culture, amyloid plaques, tau pathology, synaptic dysfunction, immune activation, genomic in-
stability, and aberrant endosome trafﬁcking. High-throughput screens can be designed to examine the impact of small molecule or other treatments upon these and other AD-like phe-
notypes directly in human neural cells. The development of novel treatments for the AD patient and the success of these treatments in the clinic completes the cycle.
3A.E. Mungenast et al. / Molecular and Cellular Neuroscience xxx (2015) xxx–xxxfrom a patient's own somatic cells and to develop patient-speciﬁc drug
treatments. Moreover, these techniques offer a nearly unlimited supply
of human cells that can be deposited in repositories and shared between
laboratories.3. Advantages to modeling neurological disease with iPS cells
The study of human brain disease is hampered by the difﬁculties in-
herent to obtaining live material. The ability to generate neural cultures
from post-mortem human brains depends greatly on the quality of the
post-mortem brain tissue (Verwer et al., 2002). Prolonged agonal states
such as hypoxia, coma, or ischemic brain damage could add confound-
ing variables to these studies (Monoranu et al., 2009). This is not to
mention the sheer difﬁculty of gaining access to reliable sources of
human brain tissue. The generation of human iPS cells is oneway to sur-
mount these limitations. Protocols have been developed to differentiate
iPS cells in vitro into distinct cell types allowing researchers to examine
disease onset and progression directly in a human culture model (see
Fig. 1). (Liu et al., 2012; Sandoe and Eggan, 2013). A number of studies
have shown successful reprogramming of iPS cells from ﬁbroblasts de-
rived from individuals with various neurological diseases such as amyo-
trophic lateral sclerosis (Dimos et al., 2008), familial dysautonomia (Lee
et al., 2009), Parkinson's disease (Park et al., 2008; Soldner et al., 2009),
Rett syndrome (Marchetto et al., 2010), schizophrenia (Brennand et al.,
2011), spinal muscular atrophy (Ebert et al., 2009; Yoshida et al., 2015),
ADA-SCID, Gaucher disease type III, Duchenne muscular dystrophy,
Becker muscular dystrophy, Down syndrome, Juvenile diabetes
mellitus, Huntington disease (Consortium, 2012; N. Zhang, 2010; Q.
Zhang, 2010), and Lesch–Nyhan syndrome (Mattis et al., 2015; Park
et al., 2008) and AD (Choi et al., 2014; Hossini et al., 2015; IovinoPlease cite this article as: Mungenast, A.E., et al., Modeling Alzheimer's
Neurosci. (2015), http://dx.doi.org/10.1016/j.mcn.2015.11.010et al., 2015; Israel et al., 2012; Koch et al., 2012; Kondo et al., 2013;
Muratore et al., 2014; Wren et al., 2015; Yagi et al., 2011; Table 1).
4. Drawbacks of iPS cells in neurological disease modeling
The explosion in human iPS cell use has underscored the need to es-
tablish standardized protocols, as cell handling and other factors can in-
ﬂuence phenotypes (Boulting et al., 2011). For example, variable X-
inactivation in cells from female donors can have an impact upon both
differentiation and phenotype (Boulting et al., 2011). Also, there is still
debate regarding to what extent DNA methylation proﬁles, and other
epigenetic attributes, might be maintained in iPS cells after
reprogramming (Kim et al., 2010; Koche et al., 2011; Nazor et al.,
2012; Ohi et al., 2011). To determine the magnitude and nature of var-
iability amongst human iPS cells, Bock et al. (2011) performed a human
genome-wide reference mapping of the DNA methylation across 20 ES
and 12 iPS cell lines. They established two scorecards for evaluating
the quality and utility of human pluripotent cell lines; this kind of tool
is crucial to the standardization of iPS protocols and is needed to obtain
comparable and reproducible results.
Genetic diversity within and between populations, aswell as disease
onset and progression, can impact the experimental read-out from iPS
cells (Rouhani et al., 2014; Soldner and Jaenisch, 2012). For example,
common DNA variants may alter expression levels and pattern of
many human genes (Majewski and Pastinen, 2011). Some groups
have sought to overcome this diversity by focusing either on fewpheno-
types in a large collection of lines (Bock et al., 2011; Rouhani et al., 2014;
Yoshimizu et al., 2015), or by investigating robust phenotypes in a
smaller cohort (Chung et al., 2013; Israel et al., 2012). Each iPS cell
study is challenged by the question of towhat extent the observed phe-
notypes are related to the disease being modeled. For example, is thedisease with human induced pluripotent stem (iPS) cells, Mol. Cell.
Table 1
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6 A.E. Mungenast et al. / Molecular and Cellular Neuroscience xxx (2015) xxx–xxxphenotype inﬂuenced by protective or exacerbating factors in the
individual's genotype? Recent advances in genome editing techniques,
particularly the use of Cas9 nuclease-based strategies, have made the
generation of isogenic iPS cell practicable (F. Zhang et al., 2014; Y.
Zhang et al., 2014;D. Zhang et al., 2014) and this technology can address
the variability inherent in the human genome to some extent.
5. Creating isogenic iPS cell lines as a strategy toovercome variability
in human genomes
The advent of homology-directed repair techniques for genome
editing proved a major advance in our ability to manipulate the
human genome. Currently, three systems have been established to per-
form DNA repair directed genome editing: zinc-ﬁnger-nucleases (ZFN),
transcription activator-like effector nucleases (TALENs), and the clus-
tered regularly interspaced short palindromic repeats (CRISPR) system
that uses the Cas9 nuclease. All these nucleases induce guided DNA
breaks. The repair of these breaks then either leads to insertion or dele-
tion (indel) mutations, or the break can be repaired by homologous re-
combination with a donor vector carrying the desired mutation (Byrne
et al., 2014). For a detailed review of the function of each of the nucle-
ases, please refer to the reviews from Hsu et al. (2014), Sander and
Joung (2014) as well as to descriptions of experimental strategies and
protocols for human pluripotent cells in particular (Byrne et al., 2014;
Chiba and Hockemeyer, 2015; Zhu et al., 2014).
The ﬁrst generation of enzyme-directed genome editing used ZFNs.
A number of important papers used the ﬁrst generation ZFNs to gener-
ate isogenic iPS cells (Carroll, 2011; Urnov et al., 2010)) by knocking
down genes such as PITX3 (Hockemeyer et al., 2009) or PIG-A (Zou
et al., 2009), or correcting disease-related mutations in genes such as
α1-anti-trypsin (Yusa et al., 2011), α-synuclein (SCNA (Ryan et al.,
2013; Soldner et al., 2011), and tau (MAPT (Fong et al., 2013). However,
the success of this technique is limited due to the challenging design of a
robust engineered zinc ﬁnger nuclease (Hsu et al., 2014;Ma et al., 2015;
Sander and Joung, 2014). The development of the second generation
TALEN technique overcame some of the limitations of the ZFNs by
being less context-dependent and easier to design (Joung and Sander,
2013; Miller et al., 2011; Sander and Joung, 2014), while the efﬁciency
is similar between the two paradigms (Hockemeyer et al., 2011).
Human iPS models established with TALEN technology include ma-
nipulations in the APOB, SORT1, AKT2, PLIN1 (Ding et al., 2013a,
2013b), PSEN1 (Woodruff et al., 2013), and DISC1 (Wen et al.,
2014). The third generation of genome editing tools is comprised of
the CRISPR/Cas9 systems, which are based on the use of the RNA-
guided Cas9 nuclease (Jinek et al., 2012; Mali et al., 2013; Ran et al.,
2013). One major advantage of the CRISPR system is that the Cas9
component is ﬁxed, and the targeting sequence is supplied via a
single-guide RNA (sgRNA); thus, targeting sequences can be easily
exchanged or multiplexed by testing multiple sgRNAs (Ding et al.,
2013a, 2013b). Several groups generated iPS cells that stably or in-
ducible express the Cas9 protein. This system allows for rapid cell-
based screens to test the consequences of multiple gene knockdowns
using sgRNA libraries (Shalem et al., 2014; Wang et al., 2014; Zhu
et al., 2014). Algorithms have been developed that predict off target
effects of CRISPR-mediated genome editing, which, combined with
falling costs for deep sequencing, allow researchers to minimize
off-target effects (Hsu et al., 2013; Tsai et al., 2015; Slaymaker et
al., 2015).
The advantage of isogenic lines is that only the disease-associated
difference is studied, as the genetic background of the lines should be
identical.While this is ideal for the study of disease causativemutations,
other genetic variants, such as a haplotype of SNPs, are more difﬁcult to
model because theymay only be relevant to disease risk in combination.
Therefore, it seems advisable to both correct the mutation of interest in
a patient-derived cell line, while in parallel introducing it in a control
line. Techniques usingmutated Cas9 linked to transcriptional activatorsPlease cite this article as: Mungenast, A.E., et al., Modeling Alzheimer's
Neurosci. (2015), http://dx.doi.org/10.1016/j.mcn.2015.11.010or repressors also allow us to examine the consequences of enhanced or
suppressed expression of speciﬁc genes without alterations to the ge-
nome itself (Qi et al., 2013). Therefore, genomeeditingwill be an impor-
tant strategy to minimize the effect of background variations in human
iPS cell-derived lines.
6. iPS cells as a model for understanding AD onset and disease
progression
In the following chapter, we will focus on studies that use iPS cells
to model AD-like phenotypes (summarized in Table 1). The two hall-
mark characteristics of AD in the human brain are ﬁrst, accumulation
of β-amyloid (Aβ) peptides into extracellular aggregates (Aβ
plaques), and second, the intracellular accumulation of phosphory-
lated species of the microtubule-associated protein tau into neuroﬁ-
brillary tangles (NFTs). Both parameters can be measured in vitro:
alterations in the presence of Aβ peptides can be measured from cul-
ture medium or cell lysates, and the ratios between different species
of Aβ peptides, such as the amount of Aβ40 versus Aβ42, are often re-
ported. To examine tauopathy in AD cellular models, the abundance
of different species of phosphorylated tau (pTau) is normalized
against total tau levels. Other AD-like phenotypes that can be mea-
sured in cultured cells will also be discussed, including endosome
cycling and DNA damage.
6.1. Phenotypic characterization of iPS cell AD models
Several groups have succeeded in creating functional neurons from
fAD and sAD iPS cells: In 2011, Yagi et al. used ﬁbroblasts of fAD patients
with mutations in either presenilin isoform PSEN1 (A246E) or PSEN2
(N141I; Yagi et al., 2011). Using retrovirus carrying a ﬁve-factor
reprogramming mix of OCT4, SOX2, KLF4, LIN28 and NANOG, they cre-
ated iPS cells that were then differentiated mainly into neuronal cells.
After two-week culturing, they observed an elevated ratio of Aβ42 to
Aβ40 for the fAD lines compared to controls. The authors did not ﬁnd
any level of tauopathy, and speculated that the two-week maturation
time may have been too short. Treatment of the cultures with the γ-
secretase inhibitors Compound E and Compound W reduced both
Aβ40 and Aβ42 levels, while only the highest dose of Compound W
appeared to impact theAβ42/40 ratio. This studywas the ﬁrst to establish
a model of fAD phenotypes in iPS cell-derived neural cultures. However
the drawbacks of this workmight be the relatively short time of neuron
maturation as well as the potential high variability between clones of
the same genotype.
In 2012, Israel et al. provided a thorough evaluation of AD-like
phenotypes in multiple iPS cell-derived neurons from both fAD and
sAD individuals (Israel et al., 2012). They used retrovirus carrying the
four Yamanaka factors OCT4, SOX2, KLF4, and c-MYC to create iPS cells
lines from healthy, non-demented individuals, two sporadic AD
patients, and two familial patients,who carriedAPP duplications. Neural
progenitor cells were puriﬁed using ﬂuorescence activated cell sorting
and differentiated into heterogeneous neuronal cultures. They observed
increased secreted Aβ40 in neurons created from one sAD and the two
fAD lines. Importantly, the Aβ levels did not differ in ﬁbroblasts from
the same individuals, supporting the idea that only distinct iPS-
derived cells can model disease-speciﬁc phenotypes. No changes were
observed in the Aβ42/40 or Aβ38/40 ratios between cell lines, although
the authors noted that detection of the less abundant Aβ42 and Aβ38
species were often below the detection range of the assay due to the
small number of neurons. In a similar pattern, one sAD and both fAD
lines showed increased phospho-tau and activation of the tau kinase
GSK3β. Treatment of the neuronal cultures with γ- and β-secretase in-
hibitors reduced Aβ40 in one sAD and one fAD line, while only β-
secretase inhibitors lowered the levels of active GSK-3β, and phospho-
tau. Another AD phenotype that can be characterized in iPS cell-
derived cultures is the presence of abnormal endosomes. Large, RAB5-disease with human induced pluripotent stem (iPS) cells, Mol. Cell.
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in the brains of sAD and fAD patients (Cataldo et al., 2001; Cataldo et al.,
2000). These endosomes may contain aberrantly phosphorylated Aβ
(Lee et al., 2003). Impaired endocytic and mitochondrial trafﬁcking
has also been observed in iPS cell models of frontotemporal dementia
(FTD) using cells from patients carrying mutations in the MAPT gene
(Iovino et al., 2015;Wren et al., 2015). Israel et al. examined early endo-
some morphology in iPS-derived neurons seeded onto a layer of
commercially-available human astrocytes, and found that the number
of medium to large RAB5+ endosomes was increased in neurons
derived from one sAD and one fAD compared to the two controls. Final-
ly, they measured synapse formation and function. No differences were
apparent in synapse number (synapsin immunoreactivity) or function
(voltage clamp recordings) between the AD and control lines.
In 2013, Kondo et al. used episomal vectors to generate iPS cells from
dermal ﬁbroblasts from both sAD patients and fAD patients carrying the
APP-V717L or the APP-E693Δ fAD mutations (Kondo et al., 2013). The
E693Δmutation leads to early-onset AD, but without amyloid deposi-
tion. Differentiated E693Δ neurons showed decreased Aβ40 and Aβ42
compared to controls, while neurons from the V717L line have
increased extracellular Aβ and an increased Aβ42/40 ratio. No signiﬁcant
Aβ secretionwas detectable in themediumof the sAD lines. The authors
then established astrocyte-rich cultures using protocols modiﬁed from
Su-Chun Zhang's work (Krencik and Zhang, 2011). Astrocytes from
the E693Δ line and one of the sAD lines accumulated Aβ oligomers
Intracellularly They performed gene expression proﬁling of the astro-
cyte/neuronal co-cultures from E693Δ and control cells and observed
that oxidative stress-related categories were upregulated in the AD
lines, suggesting ER and Golgi perturbation. The levels of these genes
were reduced following treatment with DHA, known to alleviate oxida-
tive stress, as well as the production of ROS, in E693Δ cells, without al-
tering the levels of Aβ.
Fong et al. (2013) used zinc-ﬁnger nucleases (ZFNs) to correct a
A152Tmutation in theMAPT gene (tau), as well as to create an isogenic
line homozygous for the mutation, in iPS cells (Fong et al., 2013).
Following neuronal differentiation, the heterozygous mutant tau
neurons showed short, misshapen neurites with punctate tau and
signiﬁcant phospho-tau immunoreactivity. These phenotypes were
absent in the corrected lines, and were signiﬁcantly exacerbated in
the homozygous mutant lines, which showed high degrees of
phospho-tau (AT8) and blebbing of the neurites. While they found
a low percentage of dopaminergic cells (DA) in the mutant lines,
the corrected isogenic lines had 4 to 8-fold increased number of DA
neurons.
In addition to lines derived from AD patients, several groups
have overexpressed fAD mutant versions of PSEN1 or APP in healthy
iPS or ES cell lines (Choi et al., 2014; Koch et al., 2012). For example,
neurons created from a human ES cell line were transduced, as
neuroepithelial-like stem cells, with lentivirus carrying cDNAs for
PSEN1wt, PSEN1D385N, or PSEN1L166P under control of the EF1alpha
promoter (Koch et al., 2012). By four weeks of neuronal differentia-
tion, most of the β-III tubulin-positive cells were highly immunore-
active for APP. Interestingly, the inclusion of Exon 15 of APP, a
splice variant associated with neurons, was present in neurons
after 4 weeks compared to undifferentiated cells. Extracellular Aβ
level was reduced in these neuronal cultures following treatment
with the γ-secretase inhibitor DAPT. In addition, NSAIDS, such as
ibuprofen, slightly lowered Aβ levels only in the PS1wt, but not
the PS1D385N, overexpressing neurons. One early screening
effort used commercially available iPS cell-derived neurons (iCell
Neurons) to screen a library of several hundred compounds for
their ability to ameliorate toxicity from exogenously applied Aβ
(Xu et al., 2013).
To date, most studies that model AD in patient-derived iPS cells uti-
lize cell lines with deﬁned fADmutations in PSEN1 and APP While some
studies include cells from sAD patients, the lack of a deﬁned mutationPlease cite this article as: Mungenast, A.E., et al., Modeling Alzheimer's
Neurosci. (2015), http://dx.doi.org/10.1016/j.mcn.2015.11.010means that isogenic lines cannot bemade, and often information is lack-
ing as to the severity or course of disease progression. Two studies in
which sAD lines were included observed disease phenotypes similar
to fAD cells in only one of two sAD samples (Israel et al., 2012; Kondo
et al., 2013). Few studies include sAD lines, and this is a concern, as
sporadic late-onset AD represents the vast majority of AD cases. While
60–80% of sAD may in fact have genetic underpinnings (Gatz et al.,
2006), one's APOE genotype remains the only known robust factor af-
fecting sAD risk. These issues add to the call for the development of
AD biomarkers that can predict disease risk and age of onset. Much
work has begun in this direction, and large-scale human genome-wide
association studies (GWAS) combined with mouse and human epige-
netic and transcriptome proﬁling, have derived lists of genes in which
variants are consistently associated with an increased risk of AD
(Bertram et al., 2007). These genes tend to be implicated in vesicle
trafﬁcking/endocytosis, immune function, and cholesterol metabolism
(for review see Olgiati et al., 2011)). One recent study (Young et al.,
2015) focused upon iPS cells derived from individuals with sAD-
associated variants in the SORL1 gene, which encodes a protein involved
in endocytic trafﬁcking, andwhose loss of expression has been observed
in sAD brains. The authors found that the induction of SORL1 expression
by brain-derived neurotrophic factor (BDNF) treatment, as well as the
effect of SORL1 expression upon Aβ secretion, was affected by SORL1
genotype in differentiated human neurons. While these studies were
hampered by signiﬁcant variability, which was combated by the in-
clusion of a relatively large number of cell lines, it was the ﬁrst to
describe a phenotype in human iPS cell-derived neurons resulting
from sAD-associated genetic variants. With the increased feasibility
of genome editing in iPS cells, particularly to create point mutations,
we anticipate that the near future will see many more reports eluci-
dating the roles of sAD risk variants in iPS cell-derived neural cell
models.6.2. AD phenotypes in Down syndrome iPS cells
Down syndrome (DS) patients show a high incidence of early-onset
AD-like dementia (40–60%). The underlying reasons for this are not
clear, but are presumably related to the triplication of the APP gene, as
well as the tau kinase DYRK1A gene (Woods et al., 2001) on chromo-
some 21 (Beyreuther et al., 1993; Burger and Vogel, 1973; Lemere
et al., 1996; Rumble et al., 1989). Therefore, neural cell models from
DS individuals may improve both our understanding of AD-like pathol-
ogy, as well as providing hope for therapies for DS (Editorial, 2013). To
date, no genome editing protocols have been reported that allow for the
correction or induction of trisomy in iPS cell models. However, the rare
occurrence of monozygotic twins discordant for trisomy 21 (Hibaoui
et al., 2014), as well as creation of iPS cell lines from individuals with
mosaic DS (Murray et al., 2015;Weick et al., 2013), and the spontaneous
reversion to disomy 21 in a DS iPS cell line (Maclean et al., 2012), pro-
vide us with isogenic lines with which to study this disorder. An early
paper (2008) demonstrated AD-like deﬁcits in endocytic function in ﬁ-
broblasts from DS individuals (Cataldo et al., 2008). In 2012, the Livesey
group created iPS cells from one DS patient and one control and exam-
ined them for AD-like pathology (Shi et al., 2012a, 2012b, 2012c). Inter-
estingly, the DS line secreted far higher levels of both Aβ40 and Aβ42 as
ﬁbroblasts, than did control cells. Following two months in neuronal
culture, aggregates of Aβ42 were detected in the DS cultures using live
staining with the thioﬂavin T analog BTA1 and immunocytochemistry
against Aβ42. A twenty-one day treatment with DAPT nearly abolished
both species of Aβ production in the DS neurons. Tau pathology was
also evident in neurons differentiated from DS iPS cells, detectable as
an abnormal distribution of phospho-tau within the neurons as well
as secreted tau in the medium of DS cultures only. Synapse formation
did not appear to differ between neurons from DS and control
individuals.disease with human induced pluripotent stem (iPS) cells, Mol. Cell.
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lines. Similar to Shi et al., the authors found increased immunoreactivity
for Aβ and phosphorylated tau in cells from DS individuals. Treatment
with n-butylidenephthalide (Bdph), an activator of Wnt signaling, de-
livered via coated nanoparticles, ameliorated AD-like phenotypes in
these cultures. Recently, accelerated aging phenotypes were reported
in neurons derived from DS iPS cells compared to isogenic controls
(Murray et al., 2015). Unlike previous models, these cells exhibited
differences in proliferation and differentiation. Consistent with earlier
reports, the DS iPS cell-derived neurons had increased Aβ immunoreac-
tivity inﬁxed cultures, but did not appear to differ electrophysiologically
from controls. The DS neurons also exhibit mitochondrial dysfunction
and increased DNA damage compared to the controls. This last pheno-
type is particularly interesting, and the failure of neurons to maintain
their genomic integrity appears to be a hallmark both of normal aging
and of neurodegenerative disease (Dobbin et al., 2013; Goto, 1997;
Hasty et al., 2003; Kim et al., 2008; Lovell and Markesbery, 2007; Lu
et al., 2004; Sahin and DePinho, 2010; S. Wang et al., 2013; W.Y.
Wang et al., 2013). In conclusion, iPS cell-derived neurons fromDS indi-
vidualsmay be useful formodelingphenotypes that are similar between
AD and aging inDS, as these cells appear to exhibit both amyloid and tau
pathology as well as phenotypes such as endosome dysfunction and
DNA damage.7. Disadvantages in modeling AD with iPS cells
7.1. Aging in iPS cells
Work by several groups has suggested that reprogramming of the
iPS cells “re-sets” the epigenome, and that other phenotypes associated
with cellular aging, such asmitochondrial function and telomere length,
are returned to a “juvenile-like” state (Mahmoudi and Brunet, 2012;
Miller and Studer, 2014). This raises the question: canwemodel pheno-
types associated with aging in human neural cells (Isobe et al., 2014)?
Transplantation studies of human neuronal progenitor cells (NPCs)
into the rodent brain have suggested that the human neural cells
mature on a human, rather than a rodent, timeline (Espuny-Camacho
et al., 2013). However, simply allowing iPS cells-derived neural cells to
age in vitro is impracticable and expensive. Therefore, several groups
have begun to explore the possibility of accelerated aging in these
model systems. One approach is to derive iPS cells from individuals
with Hutchinson–Gilford Progeria syndrome (HGPS), who express a
truncated product of the mutated LMNA gene, progerin, which triggers
fast aging (Blondel et al., 2014; Liu et al., 2011). Liu et al. found that
the deleterious progerin protein was absent in HGPS patient-derived
cells in the iPS cell stage (Liu et al., 2011). However, upon differentiation
to smooth muscle cells, the disease phenotype of progerin accumula-
tion, as well as its aging-associated cellular defects, were recapitulated.
In place of using patient cells, progerin can also simply be overexpressed
in iPS cells to induce age-related phenotypes such as DNA damage
and mitochondrial dysfunction (Miller et al., 2013). Increases in DNA
damage have also been observed in iPS cells derived from individuals
withWerner Syndrome, an accelerated aging disorder arising frommu-
tations in the WRN gene, which encodes a DNA helicase (Shimamoto
et al., 2015).
Instead of progerin overexpression, other “stimulating” factors
might be used to activate aging pathways. An interesting example has
been shown in cardiomyocytes from differentiated iPS cells of patients
with arrhythmogenic right ventricular dysplasia. These cells were ex-
posed to a three-factor cocktail, which activates PPARα and leads to in-
creased fatty acid oxidation instead of glycolysis (Wen et al., 2015). In
this way, the authors recapitulate the adult cardiomyocyte-like metab-
olism in these cells, which could be pushed to the desired disease pa-
thologies by further treatment with PPARγ activators. Although these
techniques appear to induce aging phenotypes in iPS cell derivatives,Please cite this article as: Mungenast, A.E., et al., Modeling Alzheimer's
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AD to incorporate systematic approaches to age neurons.
7.2. Neuronal maturation
In all iPS cell approaches, it is necessary to conﬁrm thematurity and
the functionality of the derived neurons. While some studies in neuro-
degenerative disorders use nestin and Pax6-positive NPCs as a kind of
proxy to neurons (Hossini et al., 2015), others have gone to lengths to
demonstrate the degree to which iPS cell-derived neurons model in
vivo human neurons (Israel et al., 2012). The most common methods
to conﬁrm neuronal differentiation and matureness are a combination
of immunocytochemistry and electrophysiology (Israel et al., 2012;
Nieweg et al., 2015): mature neurons should show the ability to ﬁre
action potentials when depolarized under current clamp, as well as
demonstrating spontaneous excitatory and inhibitory postsynaptic
currents under single-cell patch-clamp. Immunocytochemistry for syn-
aptic vesicle proteins, such as VGLUT1, VAMP2, synaptobrevin, and
synapsin, are indicative for mature functional synapses (Marchetto
et al., 2010; Nieweg et al., 2015). One early screening effort emphasized
the need to create mature neuronal cultures for reliable drug assays
(Yahata et al., 2011). Thus, one major challenge to researchers is to
provide neuronal cultures that are both mature enough to be represen-
tative of adult brain neurons, while being abundant enough formultiple
types of assays. Occasionally the presence of disease mutations may
hamper efforts to create human neural cell models of disease. For
example, neurons created from patient-derived iPS cells carrying FTD
mutations in MAPT have been shown to mature more quickly than
control lines, while at the same time displaying disease phenotypes
such as hyperphosphorylated Tau (Iovino et al., 2015). In contrast, an-
other group using iPS cell-derived neurons carrying the sameMAPTmu-
tation (N279K) reported that these cells had deﬁcits in neuronal
maturation compared to control lines (Wren et al., 2015). The issue of
altered proliferation and/or differentiation of neural progenitor cells
and neurons seems particularly troublesome in work with Down syn-
drome lines (Hibaoui et al., 2014; Murray et al., 2015).
7.3. Culture heterogeneity and disease phenotypes
Another important aspect is that in several studies it is not obvious
to what extent the reported neuronal cultures contain other cell types,
nor whether heterogeneous cultures may encourage neuronal differen-
tiation (Sandoe and Eggan, 2013; Shi et al., 2012a, 2012b, 2012c).While
pure cultures of neurons can form synapses and display connectivity,
they may not mature fully in the absence of astrocytes or glial-
conditioned medium (Pfrieger, 2009; Pfrieger and Barres, 1997; Ullian
et al., 2004). Along these lines, some groups have found that the
addition of astrocytes to iPS cell-derived neuronal cultures enhances
the ability to obtain mature neurons (Odawara et al., 2014; B. Zhang
et al., 2013; Y. Zhang et al., 2013); this is an area of active debate and
constant methodological improvement. Overall, it is necessary to fully
characterize the cell type matureness as well as the heterogeneity of
neural cultures derived from iPS cells. In this regard, the advent of
three-dimensional neural cultures derived from human iPS cells may
be particularly beneﬁcial, as discussed later.
Finally, a major challenge is to generate a distinct cell type to study
its involvement in a disease phenotype. It is hypothesized that only a
certain subset of cells fails in many neurological diseases, for example,
a subpopulation of dopaminergic cells in Parkinson's disease (Sandoe
and Eggan, 2013). Moreover, the phenotypes displayed by cells bearing
physiological mutations, such as familial AD mutations, may often be
less robust than those obtained via the experimental overexpression
of mutant proteins. One study compared the effect of compound treat-
ment on neural cells from fAD patients to either heterologous cell
lines overexpressing fAD APP, or human control ES-derived neural
cells overexpressing mutant APP. They observed that concentrations ofdisease with human induced pluripotent stem (iPS) cells, Mol. Cell.
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and more modestly in the APP-overexpressing human cells, had no
effect on the human neural cells carrying endogenous fADmutations
(Mertens et al., 2013). Most researchers who use patient-derived iPS
cells carrying familial mutations will be familiar with this issue of
comparatively mild disease phenotypes, at least compared tomodels
of gene overexpression or knockdown. Fortunately, the use of
isogenic lines with corrected disease alleles may, by reducing vari-
ability between lines, allow for the reliable measurement of even
modest phenotypes. The increased use of three-dimensional tissue
culture systems (see Section 8), may also facilitate disease pheno-
types by concentrating protein aggregates and other cellular prod-
ucts in a tissue-like environment that can still be imaged or
assayed with ease.
In addition to the issue of variability between iPS cell-derived
lines in assays of disease phenotypes, we are faced with the growing
awareness that other cell types must be created to model AD in
these systems. For example, in the last decade, it has become obvi-
ous that glia cells have an important impact in disease onset and
progression. Thus, our basic science interests demand that we in-
crease the complexity of our cellular models to adequately repre-
sent the disease, while at the same time we are tasked with the
production of simpliﬁed systems that are amenable to applications
such as drug screening.
8. Differentiation of iPS cells to study cell type-speciﬁc impact to-
ward neurological diseases
Generation of iPS cells typically serves as a starting point to differ-
entiate them into various brain-speciﬁc cell types such as neurons or
glial cells. Each cell lineage develops when a combination of exoge-
nousmorphogens are applied at distinct time points during develop-
ment of the iPS cells (Liu and Zhang, 2011). An alternative strategy is
the overexpression of cell type-speciﬁc transcription factors (B.
Zhang et al., 2013; Y. Zhang et al., 2013). In the following, we focus
on examples of the successful generation of neuronal and glial cell
types from human iPS cells.
8.1. Differentiation to distinct neuronal cell types
The initial iPS cell study by Takahashi et al. demonstrated the suc-
cessful generation of neuronal cells from iPS cells (Takahashi et al.,
2007). It is now common to perform neuronal differentiation
(DenhamandDottori, 2011), and even to differentiate into speciﬁc neu-
ronal subtypes, such as forebrain glutamatergic neurons (Zeng et al.,
2010), cortical neurons (Nieweg et al., 2015; Shi et al., 2012a, 2012b,
2012c), GABAergic interneurons (C.C. Liu et al., 2013; Y. Liu et al.,
2013; Nieweg et al., 2015), motor neurons (Ebert et al., 2009), and
hypothalamic-like neurons (Wang et al., 2015). Indeed, there are too
many neuronal differentiation techniques in the literature to adequate-
ly review here (some recent reviews include (Broccoli et al., 2015;
Broccoli et al., 2014; Chinchalongporn et al., 2015; Lai et al., 2015)).
The generation of inhibitory neurons is of particular interest for AD re-
search, since both inhibitory and excitatory neurons are affected (Hazra
et al., 2013; Krantic et al., 2012), and inhibitory interneurons, such as
parvalbuminergic cells, play crucial roles in orchestrating large
networks crucial to memory formation (Bartos et al., 2007; Mann and
Paulsen, 2007). The development of protocols for the differentiation of
multiple neural subtypes is a lively area of research.
8.2. Differentiation to glia
In the brain, glial cells can be divided in three major cell classes:
astrocytes, microglia, and oligodendrocytes. Each of them has been
proposed to have an important impact in AD onset and progression;
even so, it remains debatable whether alterations in glia are causativePlease cite this article as: Mungenast, A.E., et al., Modeling Alzheimer's
Neurosci. (2015), http://dx.doi.org/10.1016/j.mcn.2015.11.010for disease or represent secondary effects. Overall, human AD and
mouse gene expression studies show that, with AD progression, im-
mune response and inﬂammatory genes are up- and genes involved in
neuronal functions are down-regulated (Blalock et al., 2011; Blalock
et al., 2004; Gjoneska et al., 2015). Interestingly, GWAS describe several
AD-risk increasing genetic variants linked to genes with identiﬁed roles
in glial cells, such as APOE, PICALM, TREM2, CR1, CD33 and CLU (Ando
et al., 2013; Antunez et al., 2011; Bertram et al., 2008; Bradshaw et al.,
2013; Calero et al., 2000; Corneveaux et al., 2010; Crehan et al., 2013;
Deng et al., 2012; Guerreiro et al., 2013; Harold et al., 2009;
Hollingworth et al., 2011; Jonsson et al., 2013; Lambert et al., 2009;
Lambert et al., 2010; Wunderlich et al., 2013; N. Zhang, 2010; Q.
Zhang, 2010). Apolipoprotein (APOE) was originally identiﬁed in the
liver, where it mediates the transport and delivery of cholesterol and
other lipids through cell surface ApoE receptors (Mahley, 1988;
Mahley and Rall, 2000). The human APOE gene exists as three alleles.
While these three variants have a frequency in the population of 8.4%
(ε2), 77.9% (ε3), and 13.7% (ε4), the frequency of the APOE ε4 variant
(APOE4) is increased to at least 40% in sporadic AD patients (Farrer
et al., 1997) making it the greatest known risk factor for sAD
(Kanekiyo et al., 2014; Lambert et al., 2013). Individuals with one
APOE4 allele are three to four times more likely to develop AD than
those without APOE4 alleles, an odds ratio that is by far the highest
out of any AD risk gene (Bertram and Tanzi, 2008; Corder et al., 1993).
In both humans and in animal models, the APOE4 allele is associated
with increased levels of amyloid beta (Aβ), as well as amyloid plaque
deposition (Castellano et al., 2011; Fryer et al., 2005; Kim et al., 2009;
Youmans et al., 2012). The least common variant, APOE2, differs from
the APOE4 variant at just two amino acid positions but appears to be
protective against the development of AD (Bu, 2009; Corder et al.,
1993; Y. Liu, 2013; C.C. Liu, 2013). While the contribution of the
APOE4 allele to AD risk is well known, the reasons as towhy this variant
may trigger AD are not at all understood. The study of these APOE
variants has been particularly difﬁcult in rodentmodels, which endoge-
nously express only one version of the Apoe gene. Thus, the emergence
of iPS cell lineswith differentAPOE isotypeswill greatly advance our un-
derstanding of this AD risk factor by either collecting individuals of
particular genotypes, or by using genome editing to “switch” between
the protective and the disease-causing APOE form within the same
genotype.
Taken together, two important themes emerge from these observa-
tions: 1) neurodegeneration in ADmost likely involves an interaction of
neuronal and glial pathologies; and 2) understanding the functions of
genes implicated in AD, from GWAS or expression studies, will require
a thorough characterization of their functions in a cell type-speciﬁc
manner. Since human and mouse glia are surprisingly divergent
(Oberheim et al., 2006; Oberheim et al., 2009), which places emphasis
on the need for models of human glia for the study of neurodegenera-
tive disease.
8.2.1. Astrocytes
Astrocytes are a diverse cell class, which can differ both functionally
and morphologically between brain regions (Bribian et al., 2015; Ma
et al., 1999; Tabata, 2015) as well as displaying signiﬁcant species
divergence (Oberheim et al., 2006; Oberheim et al., 2009). Astrocytes
are intimately involved in synaptogenesis and synapse maintenance
(Haydon and Nedergaard, 2015; Pascual et al., 2005; Perea et al.,
2009), maintain brain homeostasis, store and distribute energy sub-
strates, and play a major role in the clearance of metabolites and toxins
from the brain parenchyma (Jessen et al., 2015; Xie et al., 2013). Inﬂam-
matory astrogliosis precedes or accompanies neurodegeneration in
many animal models and human postmortem AD brains, as evidenced
by increased immunoreactivity for glial ﬁbrillary acidic protein (GFAP)
as well as by the loss of important astrocytic proteins such as glutamine
synthase and GLT-1 (Dabir et al., 2006; Fischer et al., 2005; Li et al.,
1997; Masliah et al., 2000; Robinson, 2001; Tilleux and Hermans,disease with human induced pluripotent stem (iPS) cells, Mol. Cell.
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ApoE protein under physiological conditions, although cell proﬁling
studies have implicated microglia as another prominent ApoE source
(F. Zhang et al., 2014; Y. Zhang et al., 2014; D. Zhang et al., 2014).
While differentiation from iPS cells focused initially on creating
functional human neurons, several groups have now also developed
protocols to differentiate astrocytes from iPS cells. In spontaneously
differentiating cultures, astrocytes will appear roughly 100 days from
the time that neural progenitor cells are placed in differentiation
media (Shi et al., 2012a, 2012b, 2012c). Tomore quickly obtain cultures
with a higher purity of astrocytes, techniques have been developed to
obtain astrocytes from gliospheres (Krencik et al., 2011) or by directed
differentiation via deﬁned factors (Chen et al., 2014). Astrocyte-like
cells can also be obtained via direct reprogramming of ﬁbroblast cells
(Caiazzo et al., 2015). The admirable plasticity of these glial cells, how-
ever, which make them such an important and adaptable cell in the
brain, has historically led to issues of how representative primary
cultured astrocytes are compared to the in vivo situation (Foo et al.,
2011; Hertz et al., 1998; Sun et al., 2013). Given the different protocols
in development to create iPS cell-derived human astroglia, the issue of
variability between different groups and different cell lines is likely to
require a concerted effort by the entire neural iPS cell community to
address this issue.8.2.2. Microglia
Microglia are complex and dynamic cells that respond to their
environment by releasing chemical transmitters as well as phagocytos-
ing cell debris, synapses, or whole cells. Both pro-inﬂammatory and
neuroprotective roles for microglia have been demonstrated in AD.
Local resident microglia become activated and rapidly react to amy-
loid plaque formation by extending processes, migrating toward
plaques, and aggregate around them (Bolmont et al., 2008; Lue
et al., 2001). Also, microglia are demonstrated to undergo apoptosis
in AD brain (Lassmann et al., 1995; Sugaya et al., 1997; Yang et al.,
1998) and show dystrophic morphology and fragmentation, which
could underlie senescence in these cells (Streit et al., 2009; Streit
and Xue, 2010).
The differentiation of microglia from iPS cells appears possible,
though perhaps more challenging than other neural cell types, given
the unique origin of microglia (Ginhoux et al., 2010). To date, however,
while publications exist for creating mouse microglia (Beutner et al.,
2010; Beutner et al., 2013; Selvaraj et al., 2012; Tsuchiya et al., 2005), re-
sources describing human iPS cell-derivedmicroglia are rare. We found
one patent related to the “Method for obtaining human microglial pre-
cursor cells from pluripotent stem cells” (EP 2424976 A1) from the
group of Harald Neumann (Neumann et al., 2013), who also have de-
rived microglial cells from mouse ES cells (Beutner et al., 2010;
Beutner et al., 2013). Another strategy was introduced by the Filgueira
group, who generated microglia from human peripheral blood mono-
cytes using a mixture of recombinant cytokines such as M-CSF, GM-SF,
NGFβ, and CCL2 (Etemad et al., 2012). A report that focuses on the anal-
ysis of FTD phenotypes in iPS cell-derive neuronsmentions the creation
of Iba1-positive cells fromembryoid bodies, but does not further charac-
terize these cells (Almeida et al., 2012). Some groups have found that, in
the process ofmaking embryoid bodies and three-dimensional cultures,
that they are able to isolate Cd11b+/CD45+ monocyte-like cells
(Schwartz et al., 2015). However, whether these microglial precur-
sors demonstrate the same characteristics as microglia in vivo is a
matter of debate, and our understanding of microglia and their
roles in Alzheimer's disease remains woefully incomplete. To date,
we could not ﬁnd any work in the literature that focused upon creat-
ingmicroglia from human ES or iPS cells. The production of microglia
from human iPS cells is highly desirable, given our increasing aware-
ness of the role of inﬂammation in neurodegenerative disease, and
we look forward to seeing new protocols in the literature soon.Please cite this article as: Mungenast, A.E., et al., Modeling Alzheimer's
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Oligodendrocytes form myelin layers around neuronal axons in
order to allow high nerve conductance (Bercury and Macklin, 2015).
White matter lesions and myelin abnormalities have been described
in human AD brain and mouse models (Bartzokis, 2011; Desai et al.,
2010; Desai et al., 2009; Englund et al., 1988; Kobayashi et al., 2002;
Roth et al., 2005). The potential that iPS cell-derived oligodendrocyte
precursor cells and mature oligodendrocytes have for both the study
and treatment of demyelinating disorders has made this an active
ﬁeld, with a number of groups developing protocols. These studies
have generated oligodendrocytes and oligodendrocytes precursors
from human iPS cells either as a component of heterogeneous cultures
(Hu et al., 2009; Kim et al., 2012; Swistowski et al., 2010) or as the result
of concerted efforts to generate these particular cell types (Douvaras
et al., 2014; Jang et al., 2011; Ogawa et al., 2011; Pouya et al., 2011; S.
Wang et al., 2013; X.Y. Wang et al., 2013). Oligodendrocytes derived
fromhuman iPS cells have been shown tomyelinate neuronal processes
in vitro (S. Wang et al., 2013; X.Y. Wang et al., 2013) and in vivo
(Douvaras et al., 2014; Major et al., 2011; Pouya et al., 2011; S. Wang
et al., 2013; X.Y. Wang et al., 2013), and thus hold great promise for
studying the impact of myelin abnormalities in AD and other demyelin-
ating disorders.
8.3. Future challenges for cell type differentiation
For each cell type differentiation, it will be crucial to eliminate
remaining pluripotent iPS as well as progenitor cells. There are several
options such as ﬂuorescent-activated cell sorting (Sergent-Tanguy
et al., 2003) or magnetic separation, however, the processes involved
potentially risk changing the epigenetic landscape. It would be an ad-
vantage to have a marker of successful differentiation. For example,
Kim et al. (2011) showed that the microRNA-371-3 cluster could
serve as a discrimination factor for neuronal differentiation.
One major challenge will be to deﬁne what is a cell type and which
cell type is impacted in a disease phenotype. To deﬁne a cell type is
challenging by itself (DeFelipe et al., 2013; Fishell and Heintz, 2013;
Grange et al., 2014) but solving this question will be crucial for future
studies in iPS cells. This requires that we understand the phenotypic
characteristics, such as gene expression patterns, of a particular brain
cell type, so that we may determine how faithfully the iPS cell-derived
cell recapitulates the in vivo version. Oncewe know the genetic identity
of a natural cell, we can correlate this identity to our engineered cell in
vitro. Strategies like this are already proposed within the retina
(Siegert et al., 2012).
9. Modeling neurological disease in three-dimensional culture
systems
In the previous section,we discussed the impact of distinct cell types
in AD andwhat have been the current efforts in theﬁeld to generate dif-
ferent neural lineages from iPS cells. Although the analysis of a pure cell
type population can give valuable insides into the biology of the cell, it is
often the interaction between different cell types that are most impor-
tant to a truemodel of neural systems: for example, neurons exhibit in-
creased synapse formation when they are co-cultured with astrocytes
(Pfrieger and Barres, 1997), and astrocytes may look and behave differ-
ently in two-dimensional culture than they do in the brain (Cahoy et al.,
2008; Puschmann et al., 2013). The latter is a concern for all cell types,
since neurons and glia both utilize subcellular specializations, or com-
partmentalization, to function properly in vivo (Khakh and McCarthy,
2015; Tonnesen et al., 2014). In a monolayer in a culture dish, some of
this compartmentalization may be lost. One example is the observation
of calciummicrodomains in astrocytes in vivo and in slice preparations,
in which speciﬁc subregions of the astrocytic arbor exhibit restricted
calcium oscillations that may reﬂect activity to immediately adjacent
neurons (Bernardinelli et al., 2014; Di Castro et al., 2011; Shigetomidisease with human induced pluripotent stem (iPS) cells, Mol. Cell.
11A.E. Mungenast et al. / Molecular and Cellular Neuroscience xxx (2015) xxx–xxxet al., 2013). Another concern is that phenotypes of aberrant extracellu-
lar protein aggregation are lost in two-dimensional cultures simply due
to the lack of interstitial compartment, and metabolites of interest may
diffuse to the media. To overcome this, recent studies have embedded
human ES or iPS cell-derived cells in scaffolding such as hydrogel or
Matrigel, to create three dimensional culture systems (Pasca et al.,
2015; Schwartz et al., 2015; Smith et al., 2015). These kinds of culture
systems, when created with human cells overexpressing fAD proteins
or treated with Aβ oligomers, can recapitulate AD-like phenotypes
such as extracellular Aβ plaque-like deposits (Choi et al., 2014; Kim
et al., 2015) and cytoskeletal abnormalities (F. Zhang et al., 2014; Y.
Zhang et al., 2014; D. Zhang et al., 2014).
To address issues that might arise from overly simplistic culture
model systems, a number of groups have taken advantage of tissue
engineering approaches that can generate either scaffolded or self-
organizing neural cytosystems, such as “organoids”. In 2008, the Sasai
laboratory demonstrated that mouse and human ES cells could form
self-organized apico-basally polarized cortical tissue (Eiraku and Sasai,
2012; Eiraku et al., 2008). However this technique lacks the later stage
of cortical development, namely, discrete cortical layer formation with
the typically inside-out organization, as well as the presence of outer
radial glia. Lancaster et al. (2013) improved the protocol and reported
a model for human brain development in 3D organoid structure. They
observed cortical-like neuronal generation and organization, and
observed astrocytes and oligodendrocytes after more than 100 days in
vitro. To date, AD-like phenotypes have not been reported in self-
organizing three-dimensional cultures or organoids from patient-
derived cells. However, the three-dimensional cultures reported by Choi
et al., which overexpressed mutant APP, also showed an increase in
phospho-Tau levels, suggesting that it may be possible to recapitulate
many AD phenotypeswithin onemodel system,whichwould be a strong
advantage in comparison to AD mouse models (Choi et al., 2014; Kim
et al., 2015). Three-dimensional neural culture systems have yet to reca-
pitulate complex in vivo brain systems that include elements such as the
blood–brain-barrier, vascularization, or immune response, which all have
an important impact during disease and treatment. Therefore, multiple
research groups are focusing on creating vascularization, as shown for
liver tissue (Masumoto et al., 2014; Samuel et al., 2013; Takebe et al.,
2013) or blood–brain-barrier structures from iPS cells (Lippmann et al.,
2014; Lippmann et al., 2013; Lippmann et al., 2012; Minami et al., 2015).10. Conclusion
In this review, we have outlined recent strategies to investigate AD
pathology using human iPS cells and to ﬁnd new therapeutic targets
preventing disease onset and progression. The approval rate for AD
medications is a scant 4% of all treatments that enter onto Phase I trials
(McBride, 2012), while projections predict 13.8 million people with AD
and $1.2 trillion spent on AD-related care in the year 2050 (Association,
2013; Hebert et al., 2013). These numbers clearly show that newmodel
systems are needed to better translate observations from rodentmodels
into clinical studies. Human iPS cells will be an important step forward
in this direction; they have the potential to recapitulate phenotypes
from various neurological diseases in a cell type-speciﬁc manner. Creat-
ing isogenic iPS cell lines overcomeproblems of variability in human ge-
nomes and genome-editing technology has become much easier to
implement. We have outlined how iPS cells can model disease etiology,
progression, andphenotypes in humanAD. Several groups have, to date,
succeeded in recapitulating multiple AD-like phenotypes in human iPS
cells. Thus, the stage appears to be set for the widespread use of iPS
cells in preclinical drug trials for AD therapies (reviewed in (Khurana
et al., 2015)). To beneﬁtmost from these cellularmodels, it will be abso-
lutely crucial that all experiments are performed in a controlled and
standardized manner that will allow reproducibility between different
research groups.Please cite this article as: Mungenast, A.E., et al., Modeling Alzheimer's
Neurosci. (2015), http://dx.doi.org/10.1016/j.mcn.2015.11.010Several areas of iPS cell research remain topics of much debate or
even controversy. For example, there is debate over exactly how similar
iPS and ES cells are, and how well iPS cells can functionally replace ES
cells in translational research (Bock et al., 2011; Chin et al., 2009; Doi
et al., 2009; Hu et al., 2010; Narsinh et al., 2011a, 2011b). In addition
to the ethical and legal issues that have arisen regarding the creation
of ES cells, which hinder the production of new lines, a clear advantage
of iPS cells is that the donor is often an adult, sometimes elderly, and
thus can provide a health history relevant to the disorder of interest.
This is not possible with ES cells. This said, the ability to access patient
history in the use of iPS cell research is highly variable between research
groups and subject to a great deal of regulation to ensure patient privacy
(King and Perrin, 2014; Lomax et al., 2015; Lomax and Peckman, 2012;
Lomax et al., 2013). As more and more iPS cell lines are characterized
and this information added to public databases, we expect that even
researchers without direct access to patient information will beneﬁt
from these models. The development of libraries of disease-associated
iPS cell lines, of both genders, will allow high-throughput drug discov-
ery and validation, and shouldmake the rocky path from bench to clinic
shorter and straighter.
In this review, we also put a strong focus on the impact of different
cell types. It will be crucial to investigate the impact of drugs across
different cell types. The use of three-dimensional scaffolding combined
with differentiated cells (Choi et al., 2014), or the creation of self-
organizing neural tissue structures in vitro (Eiraku and Sasai, 2012;
Eiraku et al., 2008; Kadoshima et al., 2013; Lancaster et al., 2013;
Lancaster and Knoblich, 2014), hold great promise for modeling the in-
tricatemicro- andmacro-environment of the brain. In the future, it may
be possible to screen drugs in these cytosystems,which have the beneﬁt
of containingmultiple neural cell types in a physiologicalmicroenviron-
ment and, with the development of vascularization technique, may
include blood–brain barrier penetration in the assay at an early stage
of drug discovery.
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